{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-093371","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2026-08-10T20:12:20+00:00","discovered_at":"2026-08-10T20:13:01.756047+00:00","generated_at":"2026-08-10T20:13:07.457747+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TELA Bio Q2 revenue down 4% to $19.3M, withdraws FY2026 guidance","bullets":["Q2 2026 revenue $19.3M, down 4% from $20.2M; gross margin 72% vs 70%.","Net loss widened to $11.3M from $9.9M; operating loss $9.3M; cash $30.4M.","Heather Getz appointed CEO and Director effective August 4, 2026.","International revenue up 26%, OviTex units up 12%, LiquiFix revenue up 39% YoY.","Full-year 2026 revenue guidance withdrawn; company cites PRS volume decline."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-093371","json":"https://secwatch.observer/filing/0001104659-26-093371.json","markdown":"https://secwatch.observer/filing/0001104659-26-093371.md","text":"https://secwatch.observer/filing/0001104659-26-093371.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926093371/0001104659-26-093371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926093371/tm2622768d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:13:07.457747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}